GLS and neoplasm: ARID1A is a member of the SWI/SNF family, and the inhibition of GLS1 by SWI/SNF is weakened in OCCC with ARID1A mutation, which promotes Gln utilization and metabolism IN tumor cells.141 SWI/SNF mutations are present in nearly 25% of cancers, which led us to wonder whether other SWI/ SNF-mutated tumors are also sensitive to glutaminase inhibitors.142,143